6533b821fe1ef96bd127c3b3

RESEARCH PRODUCT

Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms

Juan Francisco Merino-torresAlexia AndresStefan Prado-wohlwendPilar BelloMaría Isabel Del Olmo-garcíaJosé Miguel Soriano

subject

endocrine systemQH301-705.5CellMedicine (miscellaneous)ReviewGeneral Biochemistry Genetics and Molecular BiologymedicineBiology (General)Tumorspeptide receptor radionuclide therapyReceptors d'hormonesneuroendocrine neoplasmssomatostatin analoguesSomatostatin receptorbusiness.industryTreatment optionsLU-DOTA-TATEmedicine.anatomical_structureSomatostatinPotential biomarkerssomatostatin receptorssomatostatin antagonistsCancer research68Ga PETbusinesshormones hormone substitutes and hormone antagonists

description

Neuroendocrine neoplasms (NENs) are heterogeneous neoplasms which arise from neuroendocrine cells that are distributed widely throughout the body. Although heterogenous, many of them share their ability to overexpress somatostatin receptors (SSTR) on their cell surface. Due to this, SSTR and somatostatin have been a large subject of interest in the discovery of potential biomarkers and treatment options for the disease. The aim of this review is to describe the molecular characteristics of somatostatin and somatostatin receptors and its application in diagnosis and therapy on patients with NENs as well as the use in the near future of somatostatin antagonists.

yearjournalcountryeditionlanguage
2021-12-01Biomedicines
https://doi.org/10.3390/biomedicines9121810